CAHILL EDWARD L
CIK: 0001025665
Associated companies
Transaction History
| PHR | ▲ Buy | Grant | 1,085 | $10K | 4/30/2026 | View on chart |
| PHR | ▲ Buy | Grant | 744 | $10K | 1/30/2026 | View on chart |
| PHR | ▲ Buy | Grant | 441 | $10K | 10/31/2025 | View on chart |
| PHR | ▲ Buy | Grant | 370 | $10K | 7/31/2025 | View on chart |
| PHR | ▲ Buy | Grant | 6,700 | $185K | 6/25/2025 | View on chart |
| PHR | ▲ Buy | Grant | 400 | $10K | 4/30/2025 | View on chart |
| PHR | ▲ Buy | Grant | 351 | $10K | 1/31/2025 | View on chart |
| PHR | ▲ Buy | Grant | 546 | $10K | 10/31/2024 | View on chart |
| PHR | ▲ Buy | Grant | 400 | $10K | 7/31/2024 | View on chart |
| PHR | ▲ Buy | Grant | 8,490 | $0 | 6/26/2024 | View on chart |
| PHR | ▲ Buy | Grant | 482 | $10K | 4/30/2024 | View on chart |
| PHR | ▲ Buy | Grant | 392 | $10K | 1/31/2024 | View on chart |
| PHR | ▲ Buy | Grant | 732 | $10K | 10/31/2023 | View on chart |
| PHR | ▲ Buy | Grant | 315 | $10K | 7/31/2023 | View on chart |
| PHR | ▲ Buy | Grant | 6,051 | $0 | 6/28/2023 | View on chart |
| PHR | ▲ Buy | Grant | 316 | $10K | 4/28/2023 | View on chart |
| PHR | ▲ Buy | Grant | 266 | $10K | 1/31/2023 | View on chart |
| PHR | ▲ Buy | Grant | 366 | $10K | 10/31/2022 | View on chart |
| PHR | ▲ Buy | Grant | 372 | $9K | 7/29/2022 | View on chart |
| PHR | ▲ Buy | Grant | 7,397 | $0 | 6/30/2022 | View on chart |
| PHR | ▲ Buy | Grant | 382 | $9K | 4/29/2022 | View on chart |
| PHR | ▲ Buy | Grant | 280 | $9K | 1/31/2022 | View on chart |
| PHR | ▲ Buy | Grant | 124 | $9K | 10/29/2021 | View on chart |
| PHR | ▲ Buy | Grant | 128 | $9K | 7/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Barclays Raises Phreesia Price Target to $11
Barclays has raised its price target for Phreesia to $11 while maintaining an Equal-Weight rating. This update places the firm's outlook within the broader analyst consensus, which currently averages $14.13. The stock remains well below its 52-week high of $24.07, reflecting a significant drop from previous levels.
Barclays Raises Phreesia Price Target to $11. Barclays has raised its price target for Phreesia to $11 while maintaining an Equal-Weight rating. This update places the firm's outlook within the broader analyst consensus, which currently averages $14.13. The stock remains well below its 52-week high of $24.07, reflecting a significant drop from previous levels.